MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net of...
$57,516K
Proceeds allocated to the
derivative tranche...
$14,930K
Proceeds from issuance of
pre-funded warrants, net of...
$3,601K
Proceeds from exercise of
common stock options
$51K
Net cash provided by
financing activities
$75,890K
Canceled cashflow
$208K
Net increase in
cash, cash...
$46,094K
Canceled cashflow
$29,796K
Principal payments on
finance leases
$111K
Principal payments on
financing obligation
$97K
Change in fair value of
derivative tranche...
-$29,830K
Deferred revenue
$17,115K
Stock-based compensation
expense
$3,998K
Non-cash lease expense
$1,923K
Depreciation and
amortization
$1,639K
Accrued expenses and
other liabilities
$805K
Impairment of right-of-use
asset
$494K
Loss on the sale of
property and equipment
-$258K
Non-cash interest
expense
$16K
Proceeds from the sale of
property and equipment
$36K
Net cash used in
operating activities
-$29,553K
Net cash used in
investing activities
-$243K
Canceled cashflow
$56,078K
Canceled cashflow
$36K
Net loss
-$80,403K
Purchases of property and
equipment
$279K
Operating lease assets and
liabilities
$2,996K
Accounts payable
-$1,028K
Prepaid expenses and
other current assets
$888K
Non-cash gain on lease
modification
$316K
Back
Back
Cash Flow
source: myfinsight.com
Camp4 Therapeutics Corp (CAMP)
Camp4 Therapeutics Corp (CAMP)